1. Home
  2. NVTS vs RGNX Comparison

NVTS vs RGNX Comparison

Compare NVTS & RGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NVTS
  • RGNX
  • Stock Information
  • Founded
  • NVTS 2014
  • RGNX 2008
  • Country
  • NVTS United States
  • RGNX United States
  • Employees
  • NVTS N/A
  • RGNX N/A
  • Industry
  • NVTS Semiconductors
  • RGNX Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • NVTS Technology
  • RGNX Health Care
  • Exchange
  • NVTS Nasdaq
  • RGNX Nasdaq
  • Market Cap
  • NVTS 473.3M
  • RGNX 459.1M
  • IPO Year
  • NVTS N/A
  • RGNX 2015
  • Fundamental
  • Price
  • NVTS $1.78
  • RGNX $9.63
  • Analyst Decision
  • NVTS Buy
  • RGNX Strong Buy
  • Analyst Count
  • NVTS 8
  • RGNX 12
  • Target Price
  • NVTS $4.75
  • RGNX $36.36
  • AVG Volume (30 Days)
  • NVTS 3.3M
  • RGNX 673.8K
  • Earning Date
  • NVTS 11-04-2024
  • RGNX 11-06-2024
  • Dividend Yield
  • NVTS N/A
  • RGNX N/A
  • EPS Growth
  • NVTS N/A
  • RGNX N/A
  • EPS
  • NVTS N/A
  • RGNX N/A
  • Revenue
  • NVTS $91,381,000.00
  • RGNX $84,327,000.00
  • Revenue This Year
  • NVTS $8.34
  • RGNX $7.91
  • Revenue Next Year
  • NVTS $5.50
  • RGNX $214.75
  • P/E Ratio
  • NVTS N/A
  • RGNX N/A
  • Revenue Growth
  • NVTS 38.99
  • RGNX N/A
  • 52 Week Low
  • NVTS $1.76
  • RGNX $8.54
  • 52 Week High
  • NVTS $8.44
  • RGNX $28.80
  • Technical
  • Relative Strength Index (RSI)
  • NVTS 30.33
  • RGNX 45.77
  • Support Level
  • NVTS $1.77
  • RGNX $10.24
  • Resistance Level
  • NVTS $1.93
  • RGNX $12.11
  • Average True Range (ATR)
  • NVTS 0.17
  • RGNX 0.81
  • MACD
  • NVTS -0.08
  • RGNX 0.15
  • Stochastic Oscillator
  • NVTS 1.75
  • RGNX 29.72

About NVTS Navitas Semiconductor Corporation

Navitas Semiconductor Corp develops ultra-efficient gallium nitride (GaN) semiconductors that are revolutionizing power electronics. GaN power ICs integrate GaN power with drive, control, and protection to enable fast charging, high power density, and energy savings for mobile, consumer, enterprise, eMobility, and new energy markets. The company operates as one reportable segment, the design, development, manufacture, and marketing of integrated circuits and related components for use in mobile device and other markets. Geographically, the company operates in China, Europe, United States, Rest of Asia and Others. The majority of revenue is generated from China.

About RGNX REGENXBIO Inc.

Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.

Share on Social Networks: